SCHEMBL6774393

SCHEMBL6774393

O=C(c1ccccc1Br)N(Cc1ccccc1-c1ccccc1)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ TRPM8 Q7Z2W7 1/20 0.46
▸ LMNA P02545 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ TP53 P04637 1/20 0.42
▸ THRB P10828 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HTT P42858 1/20 0.39
▸ HTR1A P08908 2/20 0.39
▸ DRD4 P21917 2/20 0.39
▸ CHRNB2 P17787 1/20 0.39
▸ CHRNB4 P30926 1/20 0.39
▸ CHRNA3 P32297 1/20 0.39
▸ CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785514 0.82 LTB4R2 (0.46) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL6781601 0.82 TP53 (0.64) TSHRALDH1A1MAPK1SMN1; SMN2TRPM8
SCHEMBL6783823 0.82 ALDH1A1 (0.47) TSHRALDH1A1SMN1; SMN2TRPM8LMNA
SCHEMBL6785117 0.82 TSHR (0.49) TSHRALDH1A1MAPK1SMN1; SMN2TRPM8
SCHEMBL6780403 0.80 TSHR (0.44) TSHRHPGDKMT2AHTT
SCHEMBL6779695 0.75 LMNA (0.49) TSHRALDH1A1LMNAPOLBTP53
SCHEMBL6778426 0.72 KMT2A (0.48) TSHRALDH1A1TP53HPGDKMT2A
SCHEMBL6783999 0.67 PTGER1 (0.47) TRPM8HTT
SCHEMBL19306196 0.66 TSHR (0.62) TSHRALDH1A1MAPK1SMN1; SMN2TRPM8
SCHEMBL6775891 0.66 PDK1 (0.47) TSHRALDH1A1SMN1; SMN2POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US claimed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US claimed
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US disclosed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein CETP, MTTP, LCAT TSHR 1297/4885ALDH1A1 646/4885MAPK1 2199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback